Endocrine Abstracts

Background: Perfluoroalkyl substances (PFAS) are endocrine disrupting chemicals, with elimination half-lives ranging from four to eight years. Experimental studies indicate that PFAS may disrupt androgenic and estrogenic pathways, potentially affecting fetal development. During 1st trimester, concentrations of sex hormone-binding globulin (SHBG) increase due to higher estrogen levels from the placenta. The increment of SHBG concentration results in a compensatory increase in t...

Background: Higher testosterone levels during pregnancy in women with polycystic ovary syndrome (PCOS) could be associated with longer offspring ano-genital distance (AGD).Aims: To compare AGD between offspring of mothers with PCOS and controls and to determine possible associations between maternal 3rd trimester testosterone levels and offspring AGD at three months of age.Methods: The study was part of the prospective s...

Background: Perfluoroalkyl substances (PFAS) are endocrine disrupting chemicals, with elimination half-lives ranging from four to eight years. Experimental studies found PFAS able to interfere with thyroid hormone-binding proteins. During the first 20 weeks of gestation (GW), the fetus is reliant on placental transfer of maternal thyroid hormones, mainly free thyroxine (FT4). However, previous studies investigating associations between exposure to PFAS and thyroid hormone stat...

Introduction: Myopathy is a known and dreaded adverse effect of pharmacological glucocorticoid (GC) treatment, but its impact on daily physical activity is not known.Aim: To measure spontaneous physical activity and musculoskeletal function in patients shortly after planned cessation of long-term (>12 weeks) prednisolone treatment.Patients and methods: Baseline data from an ongoing nation-wide prospective study (DOUBLE EDGE &#1...

Background: Glucocorticoid (GC) formulations are widely used as anti-inflammatory treatment, and synthetic GC, e.g. prednisolone, is the cornerstone treatment of polymyalgia rheumatic (PMR) and giant cell arteritis (GCA). Long-term pharmacological GC treatment may induce adrenal insufficiency (GIA). Adrenal function is, however, not routinely assessed after discontinuation of long-term GC treatment, and it is unknown, if hydrocortisone replacement is beneficial. This study aim...

Objectives: The clinical impact of glucocorticoid-induced adrenal insufficiency in patients on low-dose prednisolone is unclear. We investigated the influence of adrenal function on health-related quality of life (HRQoL) in patients tapering prednisolone.Method: Baseline data from an ongoing prospective randomised clinical trial including 278 patients with polymyalgia rheumatica/giant cell arteritis treated with prednisolone for ≥12 weeks, current ...

Background: Pharmacological glucocorticoid (GC) treatment exerts adverse effects on musculoskeletal health and may induce glucocorticoid-induced adrenal insufficiency (GIA), but these features have so far not been characterized in a prospective and unbiased manner.Aim: To characterize a population, who recently discontinued long-term (>12 weeks) prednisolone treatment with particular emphasis on the presence or absence of symptoms.<p class="abste...

Background and aim: Identifying patients with glucocorticoid-induced adrenal insufficiency poses a challenge. We investigated whether factors associated with exogenous hypercortisolism (as a proxy of overall elevated glucocorticoid exposure) could predict the risk of glucocorticoid-induced adrenal insufficiency in patients with polymyalgia rheumatica and/or giant cell arteritis during long-term low-dose prednisolone treatment.Material and methods: Baseli...

Background: Long-term prednisolone therapy may lead to subtle changes in circadian oscillations of the hypothalamic-pituitary-adrenal axis, which can affect quality of life of the patient. Low score of the Addison’s disease-specific quality-of-life questionnaire (AddiQoL-30) could be a method to assess functional glucocorticoid-induced adrenal insufficiency.Objective: To compare scores from AddiQoL-30 with generic Short Form (SF-36) questionnaire in...

Introduction: Pharmacological glucocorticoid (GC) treatment may cause iatrogenic adrenal insufficiency (GIA), although the prevalence and clinical implications are debated. With 3% of the Danish population redeeming prescriptions of systemic GC annually, the number of patients at risk is potentially extensive. Taken together, there is an unmet need for a prospective and unbiased assessment of the GIA prevalence.Materials and Methods: The data for this re...